Exhibitors

  • 0-9
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • All
BR Brazil
Stand No: 61C40
Blanver is a Brazilian multinational company with more than 30 years of experience, 3 plants in Brazil and offices in the U.S. and Spain, which develops, manufactures and markets Finished Dosage Forms (FDFs) and pharmaceutical raw materials. Our pharmaceutical business plan is to export our FDF portfolio in the HIV and HCV segment, from Brazil through strategic and meaningful partnerships. We are seeking strategic alliances with international partners of recognized quality to license and commercialize innovative and established products in segments such as Oncology and Hematology throughout Brazil and Latin America. Become our partner, contact us for more information. +55 11 4138-8200 | contatobr@blanver.com.br
Location:
Sub-event: CPHI
CN China
Stand No: 60A01
Frontier Biotechnologies Inc. is a research-based pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing significant unmet medical needs. - Its lead product candidate ALBUVIRTIDE, a novel long-acting anti-HIV agent. - The second lead drug candidate AB001 is a third generation topical patch for the management of pain and inflammation, and a phase 2 clinical trial of AB001 for the treatment of chronic low back pain was successfully completed in the US. - Frontier Biotechnologies, Inc., announced it has signed an agreement with The Rockefeller University of the US for the worldwide license for combining 3BNC117, a novel broad-spectrum HIV neutralizing antibody, with ALBUVIRTIDE for the treatment and prophylaxis of HIV infection and AIDS.
Location:
Sub-event: CPHI
IN India
Stand No: 101B79
New
Serum Institute of India Pvt Ltd (SIIPL) is the world's largest vaccine manufacturer by number of doses produced. We are ranked as India's No. 1 biotechnology company, manufacturing highly specialized vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by SIIPL. Vaccines manufactured by us are being used in more than 170 countries across the globe. 25 vaccines manufactured by SIIPL are pre-qualified by WHO for supply to UN agencies & we are the major supplier of vaccines to UNICEF and PAHO. SIIPL is actively associated with international agencies like WHO, PATH, NIBSC/HPA, Bill & Melinda Gates Foundation, CBER, Aktiv-Dry/Colorado University, EDQM, RIVM/NVI, NIH/CDC, Rhein Biotech, USAID, University of Massachusetts among others.
Location: